84470.1172743348645ce4c.pdf?id=111.81951.1172658490314] Pre-publication history The pre-publication history for this paper can be accessed here:
(2007). and the Value of Life: Whose Justice? Which Rationality? J Clin Oncol
(2000). Browning RA: Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg
(2007). Cost of Cancer Care: Issues and Implications.
(2005). Edition Montvale:Thomson PDR;
(2003). End points and United States Food and Drug Administration approval of oncology drugs.
(2006). Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm
(1998). False hopes: overcoming the obstacles to a sustainable, affordable medicine
(2007). Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference. Oncologist
(1996). Fliche E, Bressolle F: Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator.
(2007). Gel-Moreno B: Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Clin Colorectal Cancer
(2004). Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer
Insights. World Markets [http://
Italian Medicines Agency (AIFA). Official hospital drug prices [http://www.agenziafarmaco.it/ wscs_render_attachment_by_id/
(2004). Italian Trials in Medical Oncology (I.T.M.O.) Group: Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer
(2006). Managing oncology costs.
(1994). Mendelson DN: Eliminating waste and inefficiency can do little to contain costs. Health Aff (Millwood)
(2006). PJ: Do oncologists believe new cancer drugs offer good value? Oncologist
(1992). Reducing waste of intravenous solutions.
(2005). Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
(2004). Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol